Claims
- 1. A method of detecting VEGF-D in biological sample, comprising the step of contacting the sample with an antibody or an antibody labeled with a detectable label which specifically binds to a polypeptide comprising an amino acid sequence of SEQ ID NO:1, wherein said antibody is selected from the group consisting of a monoclonal antibody of 2F8 (ATCC No. PTA-3653), 4A5 (ATCC No. HB-12698), 4E10 (ATCC No. PTA-3652, and 5F12 (ATCC No. PTA-3651), or a F(ab′)2, F(ab′), or F(ab) fragment thereof, or a chimeric antibody thereof or a humanized antibody thereof, and detecting the occurrence of binding of said antibody to VEGF-D.
- 2. A method of detecting VEGF-D in biological sample, comprising the step of contacting the sample with an antibody or an antibody labeled with a detectable label which interferes with an activity of VEGF-D mediated by a VEGF receptor-2 or VEGF receptor-3, wherein said antibody is selected from the group consisting of a monoclonal antibody of 2F8 (ATCC No. PTA-3653), 4A5 (ATCC No. HB-12698), 4E10 (ATCC No. PTA-3652, and 5F12 (ATCC No. PTA-3651), or a F(ab′)2, F(ab′), or F(ab) fragment thereof, or a chimeric antibody thereof or a humanized antibody thereof, and detecting the occurrence of binding of said antibody to VEGF-D.
- 3. The method according to claim 1, wherein said antibody or said antibody labeled with a detectable label is a monoclonal antibody or a F(ab′)2, F(ab′), or F(ab) fragment thereof, or a chimeric antibody thereof.
- 4. The method according to claim 3, wherein said antibody is labeled with a detectable label.
- 5. The method according to claim 4, wherein said detectable label is a radioactive isotope.
- 6. The method according to claim 1, wherein said antibody is a humanized antibody.
- 7. The method according to claim 1, wherein said antibody is selected from the group consisting of 2F8 (ATCC No. PTA-3653), 4A5 (ATCC No. HB-12698), 4E10 (ATCC No. PTA-3652), and 5F12 (ATCC No. PTA-3651), or a F(ab′)2, F(ab′), or F(ab) fragment thereof.
- 8. The method according to claim 1, wherein said antibody is Mab 4A5 (ATCC No. HB-12698) or a F(ab′)2, F(ab′), or F(ab) fragment thereof.
- 9. The method according to claim 1, wherein said antibody interferes with an activity of VEGF-D mediated by a VEGF receptor-2, and is a monoclonal antibody, or a F(ab′)2, F(ab′), or F(ab) fragment or a chimeric antibody thereof.
- 10. The method according to claim 1, wherein said antibody interferes with the binding of VEGF-D to a VEGF receptor-3.
- 11. The method according to claim 1, wherein said antibody interferes with the binding of VEGF-D to a VEGF receptor-3, and is a monoclonal antibody, or a F(ab′)2, F(ab′), or F(ab) fragment thereof or a chimeric antibody thereof.
- 12. The method according to claim 2, wherein said antibody specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:1.
- 13. The method according to claim 2, wherein said antibody is a monoclonal antibody, or a F(ab′)2, F(ab′), or F(ab) fragment or a chimeric antibody thereof.
- 14. The method according to claim 2, wherein said antibody is labeled with a detectable label.
- 15. The method according to claim 14, wherein said detectable label is a radioactive isotope.
- 16. The method according to claim 2, wherein said antibody is a humanized antibody.
- 17. The method according to claim 2, wherein said antibody is selected from the group consisting of 2F8 (ATCC No. PTA-3653), 4A5 (ATCC No. HB-12698), 4E10 (ATCC No. PTA-3652), and 5F12 (ATCC No. PTA-3651), or a F(ab′)2, F(ab′), or F(ab) fragment thereof.
- 18. The method according to claim 2, wherein said antibody is Mab 4A5 (ATCC No. HB-12698) or a F(ab′)2, F(ab′), or F(ab) fragment thereof.
- 19. The method according to claim 2, wherein said antibody interferes with the binding of VEGF-D to a VEGF receptor-3.
- 20. The method according to claim 2, wherein said antibody interferes with the binding of VEGF-D mediated by a VEGF receptor-3, and is a monoclonal antibody, or a F(ab′)2, F(ab′), or F(ab) fragment or a chimeric antibody thereof.
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application No. 60/113,254, filed Dec. 21, 1998; and U.S. Provisional Application No. 60/134,556, filed May 17, 1999; and is a divisional application of U.S. patent application Ser. No. 09/469,186, filed Dec. 21, 1999, now U.S. Pat. No. 6,383,484.
Foreign Referenced Citations (3)
Number |
Date |
Country |
WO 9807832 |
Feb 1998 |
WO |
WO 9833917 |
Aug 1998 |
WO |
WO 9933485 |
Jul 1999 |
WO |
Non-Patent Literature Citations (7)
Entry |
Kuby et al., 1994, Immunology, second edition, pp. 85-96.* |
Abaza et al, J of Protein Chemistry 11(5): 433-444, 1992.* |
Harlow et al, in Antibodies a Laboratory Manual, 1988, Cold Spring harbor laboratory publication, Cold Spring Harbor, NY, p. 319-329, and pp. 626-629.* |
Joukov et al (EMBO J 16(13): 3898-3911, 1997.* |
U.S. patent application Ser. No. 08/915,795, filed Aug. 21, 1997. |
U.S. patent application Ser. No. 09/296,275, filed Apr. 22, 1999. |
Marc Achen et al. “Vascular Endothelial Growth Factor D (VEGF-D) is a Ligand for the Tyrosine Kinases VEGF Receptor 2 (FLK1) and VEGF Receptor 3 (FLT4)” Proc. Natl. Acad. Sci. USA, vol. 95, No. 2, pp. 548-553 (1998). XP-002066364. |
Provisional Applications (2)
|
Number |
Date |
Country |
|
60/134556 |
May 1999 |
US |
|
60/113254 |
Dec 1998 |
US |